WASHINGTON, D.C. – Jan. 12, 2020 – Global law firm Greenberg Traurig, LLP Health Care & FDA Practice Shareholder Chia-Feng Lu will co-host a webinar with L.E.K. Consulting’s Tokyo office on Jan. 13. L.E.K. Consulting is a global strategy consulting firm with clients and presence in the Americas, Europe, and Asia-Pacific.
The webinar will provide an overview of the impact that President-Elect Joe Biden’s administration may have on the attractiveness of the U.S. health care market to Japanese life sciences companies. Lu will discuss the ways in which the United States serves as an engine of growth for the global pharmaceutical market, driving much of the industry’s innovation, revenue, and profitability.
“The administration change will likely bring shifts in health care policy, potentially affecting regulation, pricing, access, and the overall commercial attractiveness of the U.S. market,” said Lu, who guides emerging technology companies, as well as industry associations, through the regulatory and transactional law surrounding life sciences and emerging technologies. “In this webinar, we look forward to reviewing the new administration’s anticipated health care policy agenda and its likely impact on the life sciences industry.”
Lu represents life sciences and emerging technology companies in strategic regulatory and legislative processes before various government agencies, to guide and develop new legislation and policy, to frame effective approaches to working with the various agencies on compliance and investigation issues, and to help clients develop strategic plans to obtain regulatory approval of their innovative products.
This includes Lu providing counsel on the development and commercialization of novel technology products, such as cell therapy, cancer immunotherapy, mobile health and digital health products, microorganism, precision medicine-related products and services, regenerative medicine, 3D-printing, etc. Among all of his representations, Lu has been involved in several products based on Nobel-winning science.
To register for this webinar, please click here.
About Greenberg Traurig’s Health Care & FDA Practice: Greenberg Traurig’s multidisciplinary Health Care & FDA Practice provides strategic counsel to a diverse group of companies and other organizations, helping them to responds proactively to the rapidly changing healthcare marketplace. The group combine dedicated experience in health care regulatory compliance and operational matters with the firm’s capabilities in corporate & securities, finance, tax, antitrust, ERISA, commercial and governmental litigation, restructuring, intellectual property and biotechnology, in order to provide a wide range of legal services.
About Greenberg Traurig: Greenberg Traurig, LLP (GT), has approximately 2200 attorneys in 40 locations in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, diversity, and innovation, and is consistently among the largest firms in the U.S. on the Law360 400 and among the Top 20 on the Am Law Global 100. The firm is net carbon neutral with respect to its office energy usage and Mansfield Rule 3.0 Certified. Web: www.gtlaw.com